AU2002234047A1 - Pyrazole compounds useful as protein kinase inhibitors - Google Patents

Pyrazole compounds useful as protein kinase inhibitors

Info

Publication number: AU2002234047A1
Authority: AU; Australia
Prior art keywords: protein kinase; kinase inhibitors; compounds useful; pyrazole compounds; pyrazole
Prior art date: 2000-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002234047A

Inventor

David Bebbington

Jean-Damien Charrier

Robert Davies

Simon Everitt

David Kay

Ronald Knegtel

Sanjay Patel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Vertex Pharmaceuticals Inc

Original Assignee

Vertex Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-21

Filing date

2001-12-19

Publication date

2002-07-01

2001-12-19 Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc

2002-07-01 Publication of AU2002234047A1 publication Critical patent/AU2002234047A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Psychology (AREA)
Biotechnology (AREA)
Emergency Medicine (AREA)

AU2002234047A 2000-12-21 2001-12-19 Pyrazole compounds useful as protein kinase inhibitors Abandoned AU2002234047A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US25788700P	2000-12-21	2000-12-21
US60/257,887		2000-12-21
US28694901P	2001-04-27	2001-04-27
US60/286,949		2001-04-27
PCT/US2001/049140 WO2002050065A2 (en)	2000-12-21	2001-12-19	Pyrazole compounds useful as protein kinase inhibitors

Publications (1)

Publication Number	Publication Date
AU2002234047A1 true AU2002234047A1 (en)	2002-07-01

Family

ID=26946273

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
AU2001297619A Ceased AU2001297619B2 (en)	2000-12-21	2001-12-19	Pyrazole compounds useful as protein kinase inhibitors
AU2002255452A Ceased AU2002255452B2 (en)	2000-12-21	2001-12-19	Pyrazole compounds useful as protein kinase inhibitors
AU2002234047A Abandoned AU2002234047A1 (en)	2000-12-21	2001-12-19	Pyrazole compounds useful as protein kinase inhibitors
AU2002246754A Ceased AU2002246754B2 (en)	2000-12-21	2001-12-20	Pyrazole compounds useful as protein kinase inhibitors
AU2002231166A Ceased AU2002231166B2 (en)	2000-12-21	2001-12-20	Pyrazole compounds useful as protein kinase inhibitors
AU3116602A Pending AU3116602A (en)	2000-12-21	2001-12-20	Pyrazole compounds useful as protein kinase inhibitors
AU2006201267A Ceased AU2006201267B2 (en)	2000-12-21	2006-03-21	Pyrazole Compounds Useful as Protein Kinase Inhibitors

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
AU2001297619A Ceased AU2001297619B2 (en)	2000-12-21	2001-12-19	Pyrazole compounds useful as protein kinase inhibitors
AU2002255452A Ceased AU2002255452B2 (en)	2000-12-21	2001-12-19	Pyrazole compounds useful as protein kinase inhibitors

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
AU2002246754A Ceased AU2002246754B2 (en)	2000-12-21	2001-12-20	Pyrazole compounds useful as protein kinase inhibitors
AU2002231166A Ceased AU2002231166B2 (en)	2000-12-21	2001-12-20	Pyrazole compounds useful as protein kinase inhibitors
AU3116602A Pending AU3116602A (en)	2000-12-21	2001-12-20	Pyrazole compounds useful as protein kinase inhibitors
AU2006201267A Ceased AU2006201267B2 (en)	2000-12-21	2006-03-21	Pyrazole Compounds Useful as Protein Kinase Inhibitors

Country Status (27)

Country	Link
US (16)	US6653301B2 (en)
EP (10)	EP1353916B1 (en)
JP (19)	JP4160395B2 (en)
KR (8)	KR100889246B1 (en)
CN (6)	CN100406454C (en)
AP (2)	AP2003002825A0 (en)
AR (4)	AR042169A1 (en)
AT (9)	ATE327989T1 (en)
AU (7)	AU2001297619B2 (en)
BR (2)	BR0116493A (en)
CA (8)	CA2432222C (en)
CY (1)	CY1106297T1 (en)
DE (8)	DE60119775T2 (en)
DK (3)	DK1355905T3 (en)
ES (7)	ES2265452T3 (en)
HU (5)	HUP0400641A3 (en)
IL (8)	IL156368A0 (en)
MX (8)	MXPA03005609A (en)
MY (1)	MY140377A (en)
NO (5)	NO20032671L (en)
NZ (8)	NZ526470A (en)
PL (2)	PL210414B1 (en)
PT (3)	PT1355905E (en)
RU (1)	RU2355688C2 (en)
SI (2)	SI1353916T1 (en)
TW (2)	TWI313269B (en)
WO (8)	WO2002050065A2 (en)

Families Citing this family (380)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6982260B1 (en)	1999-11-22	2006-01-03	Warner-Lambert Company	Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (en) *	2000-09-15	2006-11-22	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
MXPA03005001A (en) *	2000-12-05	2003-09-05	Vertex Pharma	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases.
CA2432222C (en)	2000-12-21	2008-07-29	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US20030125344A1 (en) *	2001-03-23	2003-07-03	Bayer Corporation	Rho-kinase inhibitors
US7034026B2 (en)	2001-04-10	2006-04-25	Merck & Co., Inc.	Inhibitors of Akt activity
US7105667B2 (en) *	2001-05-01	2006-09-12	Bristol-Myers Squibb Co.	Fused heterocyclic compounds and use thereof
US7138404B2 (en) *	2001-05-23	2006-11-21	Hoffmann-La Roche Inc.	4-aminopyrimidine derivatives
US7115617B2 (en)	2001-08-22	2006-10-03	Amgen Inc.	Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en)	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
EA007430B1 (en) *	2001-09-26	2006-10-27	Фармация Италия С.П.А.	Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2003026666A1 (en) *	2001-09-26	2003-04-03	Bayer Pharmaceuticals Corporation	2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
SE0104140D0 (en)	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
US20030187026A1 (en)	2001-12-13	2003-10-02	Qun Li	Kinase inhibitors
AU2002361846A1 (en) *	2001-12-21	2003-07-15	Bayer Pharmaceuticals Corporation	Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
CN100409840C (en)	2002-01-10	2008-08-13	霍夫曼-拉罗奇有限公司	Application of GSK-3β inhibitor in preparation of medicine for increasing bone formation
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
JP4656838B2 (en) *	2002-02-06	2011-03-23	バーテックスファーマシューティカルズインコーポレイテッド	Heteroaryl compounds useful as inhibitors of GSK-3
US7179826B2 (en)	2002-03-15	2007-02-20	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
US20040009981A1 (en) *	2002-03-15	2004-01-15	David Bebbington	Compositions useful as inhibitors of protein kinases
WO2003077921A1 (en) *	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azinylaminoazoles as inhibitors of protein kinases
EP1496896A4 (en)	2002-04-08	2007-10-31	Merck & Co Inc	INHIBITORS OF AKT ACTIVITY
US7524852B2 (en)	2002-06-07	2009-04-28	Kyowa Hakko Kogyo Co., Ltd.	Bicyclic pyrimidine derivatives
MY141867A (en)	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
EP1551841A1 (en) *	2002-07-23	2005-07-13	SmithKline Beecham Corporation	Pyrazolopyrimidines as kinase inhibitors
MXPA05001096A (en)	2002-07-29	2005-11-23	Rigel Pharmaceuticals Inc	Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds.
EP1739087A1 (en) *	2002-08-02	2007-01-03	Vertex Pharmaceuticals Incorporated	Pyrazole compositions useful as inhibitors of gsk-3
CN101037438A (en) *	2002-08-02	2007-09-19	沃泰克斯药物股份有限公司	Compositions useful as inhibitors of GSK-3
BR0314098A (en)	2002-09-05	2005-07-19	Aventis Pharma Sa	Aminoindazole derivatives as medicines and pharmaceutical compositions containing them
FR2844267B1 (en) *	2002-09-05	2008-02-15	Aventis Pharma Sa	NOVEL DERIVATIVES OF AMINOINDAZOLES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
WO2004030672A1 (en) *	2002-10-02	2004-04-15	Merck Patent Gmbh	Use of 4 amino-quinazolines as anti cancer agents
CA2500952C (en)	2002-10-04	2011-04-26	Prana Biotechnology Limited	Neurologically-active compounds
KR100490893B1 (en) *	2002-10-11	2005-05-23	(주) 비엔씨바이오팜	2-methoxy-1,3,5-triazine derivatives, method for preparing thereof and antiviral pharmaceutical composition comprising the same
GB0226583D0 (en) *	2002-11-14	2002-12-18	Cyclacel Ltd	Compounds
US7462613B2 (en)	2002-11-19	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
FR2847253B1 (en) *	2002-11-19	2007-05-18	Aventis Pharma Sa	NOVEL DERIVATIVES OF PYRIDAZINONES AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
US7309701B2 (en)	2002-11-19	2007-12-18	Sanofi-Aventis Deutschland Gmbh	Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
MXPA05005477A (en)	2002-11-21	2005-07-25	Chiron Corp	2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer.
WO2004072029A2 (en) *	2003-02-06	2004-08-26	Vertex Pharmaceuticals Incorporated	Pyrazolopyridazines useful as inhibitors of protein kinases
US7157455B2 (en) *	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives
WO2004087679A1 (en) *	2003-04-01	2004-10-14	Aponetics Ag	2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
ES2308182T3 (en) *	2003-06-02	2008-12-01	Astrazeneca Ab	DERIVATIVES OF (3 - ((QUINAZOLIN-4-IL) AMINO) -1H-PIRAZOL-1-IL) ACETAMIDE AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER.
US7560467B2 (en)	2003-06-19	2009-07-14	Smithkline Beecham Corporation	Indazolo-tetrahydropyrimidine-carboxamide derivative kinase inhibitors
US8309562B2 (en)	2003-07-03	2012-11-13	Myrexis, Inc.	Compounds and therapeutical use thereof
TWI372050B (en) *	2003-07-03	2012-09-11	Astex Therapeutics Ltd	(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
CN1984660B (en) *	2003-07-03	2010-12-15	美瑞德生物工程公司	4-Arylamino-quinazolines as caspase-specific activators and inducers of apoptosis
GB0315966D0 (en) *	2003-07-08	2003-08-13	Cyclacel Ltd	Compounds
EP2256106B1 (en)	2003-07-22	2015-05-06	Astex Therapeutics Limited	3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
AU2004265288A1 (en)	2003-07-30	2005-02-24	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
AU2004261484A1 (en) *	2003-07-30	2005-02-10	Cyclacel Limited	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
US7417726B2 (en) *	2003-09-19	2008-08-26	Applied Biosystems Inc.	Normalization of data using controls
US20060024690A1 (en) *	2003-09-19	2006-02-02	Kao H P	Normalization of data using controls
US20050221357A1 (en) *	2003-09-19	2005-10-06	Mark Shannon	Normalization of gene expression data
US20050124562A1 (en) *	2003-09-23	2005-06-09	Joseph Guiles	Bis-quinazoline compounds for the treatment of bacterial infections
JP2007510626A (en)	2003-10-17	2007-04-26	アストラゼネカアクチボラグ	4- (Pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
US7592340B2 (en) *	2003-12-04	2009-09-22	Vertex Pharmaceuticals Incorporated	Quinoxalines useful as inhibitors of protein kinases
WO2005056552A1 (en) *	2003-12-09	2005-06-23	Vertex Pharmaceuticals Incorporated	Naphthyridine derivatives and their use as modulators of muscarinic receptors
US7572914B2 (en)	2003-12-19	2009-08-11	Takeda Pharmaceutical Company Limited	Kinase inhibitors
TW200530235A (en)	2003-12-24	2005-09-16	Renovis Inc	Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
AU2005212438A1 (en)	2004-02-11	2005-08-25	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
US20080050314A1 (en) *	2004-02-26	2008-02-28	Bayer Healthcare Ag	Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b)
JP4875978B2 (en) *	2004-03-15	2012-02-15	武田薬品工業株式会社	Aminophenylpropanoic acid derivatives
WO2005099688A2 (en) *	2004-04-07	2005-10-27	Takeda Pharmaceutical Company Limited	Cyclic compounds
WO2005103010A2 (en) *	2004-04-21	2005-11-03	Astrazeneca Ab	Pyrazole derivatives useful for the treatment of cancer
EP1763524A1 (en) *	2004-04-23	2007-03-21	Takeda San Diego, Inc.	Indole derivatives and use thereof as kinase inhibitors
EP1751136B1 (en) *	2004-05-07	2014-07-02	Amgen Inc.	Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
US7793137B2 (en)	2004-10-07	2010-09-07	Cisco Technology, Inc.	Redundant power and data in a wired data telecommunincations network
KR20070012555A (en) *	2004-05-14	2007-01-25	버텍스 파마슈티칼스 인코포레이티드	Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
AU2012200416B2 (en) *	2004-05-14	2014-07-31	Millennium Pharmaceuticals, Inc.	"Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
US20050255485A1 (en) *	2004-05-14	2005-11-17	Livak Kenneth J	Detection of gene duplications
US7572784B2 (en) *	2004-05-14	2009-08-11	Millennium Pharmaceuticals, Inc.	Compounds and methods for inhibiting mitotic progression
PL1905773T3 (en) *	2004-05-14	2012-12-31	Millennium Pharm Inc	Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2005112923A2 (en) *	2004-05-20	2005-12-01	Bayer Pharmaceuticals Corporation	5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
EP1756673A1 (en) *	2004-05-27	2007-02-28	E.I.Du pont de nemours and company	Developer for a photopolymer protective layer
US7872005B2 (en) *	2004-07-01	2011-01-18	Synta Pharmaceuticals Corporation	2-substituted heteroaryl compounds
CA2573103A1 (en) *	2004-07-06	2006-02-09	Angion Biomedica Corporation	Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
US7550598B2 (en) *	2004-08-18	2009-06-23	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US7285569B2 (en)	2004-09-24	2007-10-23	Hoff Hoffmann-La Roche Inc.	Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) *	2004-09-24	2006-07-16	Hoffmann La Roche	Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
RU2405778C2 (en) *	2004-09-30	2010-12-10	Тиботек Фармасьютикалз Лтд.	Hiv inhibiting 5-heterocyclyl pyrimidines
TW200626561A (en) *	2004-09-30	2006-08-01	Tibotec Pharm Ltd	HIV inhibiting 5-substituted pyrimidines
KR20070057798A (en) *	2004-09-30	2007-06-07	티보텍 파마슈티칼즈 리미티드	Pyrimidine substituted with 5-carbocycle or heterocycle that inhibits HIV
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
EP1828165B1 (en) *	2004-10-29	2013-03-20	Msd K.K.	Novel aminopyridine derivatives having aurora a selective inhibitory action
US7491720B2 (en) *	2004-10-29	2009-02-17	Banyu Pharmaceutical Co., Ltd.	Aminopyridine derivatives having Aurora A selective inhibitory action
EP1809290A2 (en)	2004-11-03	2007-07-25	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as ion channel modulators and methods of use
CA2587427A1 (en)	2004-11-17	2006-05-26	Miikana Therapeutics, Inc.	Kinase inhibitors
US7557207B2 (en)	2004-11-24	2009-07-07	Rigel Pharmaceuticals, Inc.	Spiro 2,4-pyrimidinediamine compounds and their uses
US20060128710A1 (en) *	2004-12-09	2006-06-15	Chih-Hung Lee	Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
JP2008525422A (en) *	2004-12-23	2008-07-17	ファイザー・プロダクツ・インク	Heteroaromatic derivatives useful as anticancer agents
WO2006074057A2 (en)	2004-12-30	2006-07-13	Exelixis, Inc.	Pyrimidine derivatives as kinase modulators and method of use
CA2593993C (en) *	2004-12-30	2014-07-29	Astex Therapeutics Limited	Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases
CA2592900A1 (en)	2005-01-03	2006-07-13	Myriad Genetics Inc.	Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en)	2005-01-03	2012-09-04	Myrexis, Inc.	Method of treating brain cancer
CN101115761B (en)	2005-01-19	2012-07-18	里格尔药品股份有限公司	Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8404718B2 (en)	2005-01-21	2013-03-26	Astex Therapeutics Limited	Combinations of pyrazole kinase inhibitors
AR054425A1 (en) *	2005-01-21	2007-06-27	Astex Therapeutics Ltd	PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
CN101146796A (en) *	2005-01-26	2008-03-19	先灵公司	3-(Indazol-5-yl)-(1,2,4)triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer
SI1846394T1 (en)	2005-02-04	2012-06-29	Astrazeneca Ab	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
SI1853602T1 (en) *	2005-02-16	2010-11-30	Astrazeneca Ab	Chemical compounds
BRPI0607455A2 (en) *	2005-02-16	2009-09-01	Astrazeneca Ab	compound, process for preparing same, use of a compound, and pharmaceutical composition
BRPI0608513A2 (en) *	2005-03-15	2010-01-05	Irm Llc	compounds and compositions as protein kinase inhibitors
US20080161278A1 (en) *	2005-03-23	2008-07-03	Astrazeneca Ab	2-Azetidinyl-4-(1H-Pyrazol-3-Ylamino) Pyrimidines as Inhibitors of Insulin-Like Growth Factor-1 Receptor Activity
US7402596B2 (en)	2005-03-24	2008-07-22	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JP2008534662A (en) *	2005-04-05	2008-08-28	アストラゼネカアクチボラグ	Pyrimidine derivatives used as anticancer agents
GB0507347D0 (en) *	2005-04-12	2005-05-18	Astrazeneca Ab	Chemical compounds
EP1879894A1 (en)	2005-04-14	2008-01-23	F.Hoffmann-La Roche Ag	Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
CN101208093A (en) *	2005-04-27	2008-06-25	阿斯利康(瑞典)有限公司	Use of pyrazole-pyrimidine derivatives in the treatment of pain
EP1876178B1 (en) *	2005-04-28	2015-05-27	Mitsubishi Tanabe Pharma Corporation	Cyanopyridine derivative and use thereof as medicine
WO2006117212A2 (en)	2005-05-04	2006-11-09	Develogen Aktiengesellschaft	Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
ES2552804T3 (en)	2005-05-04	2015-12-02	Evotec Ag	Condensed heterocyclic compounds, and their compositions and uses
WO2006117560A1 (en) *	2005-05-05	2006-11-09	Astrazeneca Ab	Pyrazolyl-amino- substituted pyrimidines and their use in the treatment of cancer
JP2008540622A (en) *	2005-05-16	2008-11-20	アストラゼネカアクチボラグ	Compound
NZ563454A (en)	2005-06-08	2011-03-31	Rigel Pharmaceuticals Inc	2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US8193206B2 (en)	2005-06-14	2012-06-05	Taigen Biotechnology Co., Ltd.	Pyrimidine compounds
KR101354114B1 (en)	2005-06-14	2014-01-24	타이젠 바이오테크놀러지 컴퍼니 리미티드	Pyrimidine compounds
EP1746096A1 (en)	2005-07-15	2007-01-24	4Sc Ag	2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
EP1917259B1 (en) *	2005-08-18	2012-01-25	Vertex Pharmaceuticals Incorporated	Pyrazine kinase inhibitors
WO2007023382A2 (en) *	2005-08-25	2007-03-01	Pfizer Inc.	Pyrimidine amino pyrazole compounds, potent kinase inhibitors
EP2258358A3 (en)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (en)	2005-08-26	2009-02-12	ブレインセルス，インコーポレイティド	Neurogenesis through modulation of muscarinic receptors
CN101316587B (en) *	2005-09-30	2013-04-03	迈卡纳治疗股份有限公司	Substituted pyrazole compounds
NZ567241A (en)	2005-09-30	2010-08-27	Miikana Therapeutics Inc	Substituted pyrazole compounds
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
JP2009512711A (en)	2005-10-21	2009-03-26	ブレインセルス，インコーポレイティド	Regulation of neurogenesis by PDE inhibition
EP1945631B8 (en)	2005-10-28	2013-01-02	AstraZeneca AB	4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
JP2009513672A (en)	2005-10-31	2009-04-02	ブレインセルス，インコーポレイティド	GABA receptor-mediated regulation of neurogenesis
AU2006309173B2 (en) *	2005-11-01	2011-08-18	Array Biopharma Inc.	Glucokinase activators
SG166827A1 (en) *	2005-11-03	2010-12-29	Vertex Pharma	Aminopyrimidines useful as kinase inhibitors
CN101360740A (en) *	2005-11-16	2009-02-04	沃泰克斯药物股份有限公司	Aminopyrimidines useful as kinase inhibitors
US8546404B2 (en)	2005-12-13	2013-10-01	Merck Sharp & Dohme	Compounds that are ERK inhibitors
US7572809B2 (en)	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
EP1968579A1 (en)	2005-12-30	2008-09-17	Astex Therapeutics Limited	Pharmaceutical compounds
US20080058312A1 (en) *	2006-01-11	2008-03-06	Angion Biomedica Corporation	Modulators of hepatocyte growth factor/c-Met activity
JO2660B1 (en)	2006-01-20	2012-06-17	نوفارتيس ايه جي	PI-3 Kinase inhibitors and methods of their use
WO2007097937A1 (en) *	2006-02-16	2007-08-30	Schering Corporation	Pyrrolidine derivatives as erk inhibitors
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
PE20080145A1 (en) *	2006-03-21	2008-02-11	Janssen Pharmaceutica Nv	TETRAHYDRO-PYRIMIDOAZEPINE AS MODULATORS OF TRPV1
CN101405283B (en) *	2006-03-30	2014-06-18	泰博特克药品有限公司	HIV inhibiting 5-amido substituted pyrimidines
EP2001480A4 (en) *	2006-03-31	2011-06-15	Abbott Lab	Indazole compounds
JP2009532440A (en)	2006-04-07	2009-09-10	ノバルティスアクチエンゲゼルシャフト	A combination comprising a) a pyrimidylaminobenzamide compound and b) a Thr315Ile kinase inhibitor
WO2007118276A1 (en)	2006-04-14	2007-10-25	Prana Biotechnology Ltd	Method of treatment of age-related macular degeneration(amd)
WO2007126126A1 (en) *	2006-04-27	2007-11-08	Banyu Pharmaceutical Co., Ltd.	Novel aminopyridine derivative having aurora-a-selective inhibitory activity
WO2007134077A2 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
AU2007249399A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	Neurogenesis by modulating angiotensin
US7732626B2 (en)	2006-06-27	2010-06-08	Takeda Pharmaceutical Company Limited	Fused cyclic compounds
US20110159111A1 (en) *	2006-06-29	2011-06-30	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008001115A2 (en)	2006-06-29	2008-01-03	Astex Therapeutics Limited	Pharmaceutical combinations of 1-cyclopropyl-3- [3- (5-m0rphoolin-4-ylmethyl-1h-benzoimidazol-2-yl) -lh-1-pyrazol- 4-yl] -urea
EP2036894A4 (en) *	2006-06-30	2011-01-12	Kyowa Hakko Kirin Co Ltd	Aurora inhibitor
UY30444A1 (en) *	2006-06-30	2008-01-31	Astrazeneca Ab	PIRIMIDINE DERIVATIVES, PROCESSES FOR PREPARATION, PHARMACCUTIC COMPOSITIONS AND USES OF THE SAME.
WO2008005538A2 (en)	2006-07-05	2008-01-10	Exelixis, Inc.	Methods of using igf1r and abl kinase modulators
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008021038A2 (en) *	2006-08-09	2008-02-21	Millennium Pharmaceuticals, Inc.	Pyridobenzazepine compounds and methods for inhibiting mitotic progression
US7832809B2 (en) *	2006-08-11	2010-11-16	Schlumberger Technology Corporation	Degradation assembly shield
JP2008081492A (en)	2006-08-31	2008-04-10	Banyu Pharmaceut Co Ltd	Novel aminopyridine derivatives having selective inhibition of Aurora A
MX2009002496A (en)	2006-09-08	2009-07-10	Braincells Inc	Combinations containing a 4-acylaminopyridine derivative.
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
BRPI0719883A2 (en)	2006-10-09	2015-05-05	Takeda Pharmaceutical	Kinase Inhibitors
JP2010505961A (en) *	2006-10-09	2010-02-25	タケダサンディエゴインコーポレイテッド	Kinase inhibitor
US8916552B2 (en)	2006-10-12	2014-12-23	Astex Therapeutics Limited	Pharmaceutical combinations
US8883790B2 (en)	2006-10-12	2014-11-11	Astex Therapeutics Limited	Pharmaceutical combinations
WO2008053812A1 (en) *	2006-10-27	2008-05-08	Mitsubishi Tanabe Pharma Corporation	Cyanopyridine derivative and medicinal use thereof
MX2009004807A (en) *	2006-11-02	2009-06-15	Vertex Pharma	Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases.
CL2007003244A1 (en)	2006-11-16	2008-04-04	Millennium Pharm Inc	COMPOUNDS DERIVED FROM PIRIMIDO [5,4-D] [2] BENZAZEPINA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
DE602007007985D1 (en) *	2006-12-19	2010-09-02	Vertex Pharma	AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINO-PRIMIDINES
MX2009007006A (en) *	2006-12-29	2009-07-09	Tibotec Pharm Ltd	Hiv inhibiting 5,6-substituted pyrimidines.
ES2470570T3 (en) *	2006-12-29	2014-06-24	Janssen R&D Ireland	HIV-substituted 6-position substituted pyrimidines
CA2675558A1 (en)	2007-02-06	2008-08-14	Novartis Ag	Pi 3-kinase inhibitors and methods of their use
KR20090115866A (en)	2007-03-05	2009-11-09	교와 핫꼬 기린 가부시키가이샤	Medicinal composition
CN101663295B (en) *	2007-03-09	2014-11-05	沃泰克斯药物股份有限公司	Aminopyrimidines useful as inhibitors of protein kinases
MX2009009592A (en) *	2007-03-09	2009-11-10	Vertex Pharma	Aminopyridines useful as inhibitors of protein kinases.
MX2009009591A (en) *	2007-03-09	2009-11-10	Vertex Pharma	Aminopyrimidines useful as inhibitors of protein kinases.
CN101675041A (en) *	2007-03-20	2010-03-17	沃泰克斯药物股份有限公司	Amino-metadiazine compound as kinase inhibitor
WO2008117050A1 (en) *	2007-03-27	2008-10-02	Astrazeneca Ab	Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
CN101679386A (en)	2007-04-13	2010-03-24	沃泰克斯药物股份有限公司	Aminopyrimidines useful as kinase inhibitors
MX2009011090A (en)	2007-04-18	2009-11-02	Pfizer Prod Inc	Sulfonyl amide derivatives for the treatment of abnormal cell growth.
WO2008129255A1 (en) *	2007-04-18	2008-10-30	Astrazeneca Ab	5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
WO2008137621A1 (en) *	2007-05-02	2008-11-13	Vertex Pharmaceuticals Incorporated	Aminopyrimidines useful as kinase inhibitors
MX2009011811A (en) *	2007-05-02	2010-01-14	Vertex Pharma	Aminopyrimidines useful as kinase inhibitors.
EP2152694A2 (en)	2007-05-02	2010-02-17	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
CN101687863B (en) *	2007-05-04	2012-09-12	阿斯利康(瑞典)有限公司	Amino-thiazolyl-pyrimidine derivatives and their use in the treatment of cancer
UA99459C2 (en)	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
AU2008257044A1 (en) *	2007-05-24	2008-12-04	Vertex Pharmaceuticals Incorporated	Thiazoles and pyrazoles useful as kinase inhibitors
KR101294731B1 (en) *	2007-06-04	2013-08-16	삼성디스플레이 주식회사	Array substrate, display panel having the array substrate and method of manufacturing the array substrate
US20090029992A1 (en) *	2007-06-11	2009-01-29	Agoston Gregory E	Substituted pyrazole compounds
JP2010532756A (en) *	2007-07-06	2010-10-14	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	Combination anti-cancer therapy comprising inhibitors of both mTORC1 and mTORC2
WO2009007753A2 (en) *	2007-07-11	2009-01-15	Astrazeneca Ab	4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
US8415340B2 (en) *	2007-07-25	2013-04-09	Bristol-Myers Squibb Company	Triazine kinase inhibitors
WO2009013545A2 (en) *	2007-07-26	2009-01-29	Astrazeneca Ab	Chemical compounds
CA2694499A1 (en)	2007-07-31	2009-02-05	Vertex Pharmaceuticals Incorporated	Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
TW200906818A (en) *	2007-07-31	2009-02-16	Astrazeneca Ab	Chemical compounds
EP2025674A1 (en)	2007-08-15	2009-02-18	sanofi-aventis	Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2009027736A2 (en) *	2007-08-27	2009-03-05	Astrazeneca Ab	2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
AU2008305294B2 (en)	2007-09-21	2012-11-29	Array Biopharma Inc.	Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
NZ584471A (en)	2007-10-11	2012-01-12	Glaxosmithkline Llc	Triazine cyclohexane carboxamide compounds and their use
JP5562865B2 (en)	2007-12-17	2014-07-30	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	TRPV1 imidazolo-, oxazolo-, and thiazolopyrimidine modulators
US20090270418A1 (en) *	2008-01-09	2009-10-29	Marianne Sloss	Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
EP2242745A1 (en) *	2008-02-07	2010-10-27	Sanofi-Aventis	Novel phenyl-substituted imidazolidines, method for the production thereof, medicaments containing said compounds and use thereof
WO2009105500A1 (en)	2008-02-21	2009-08-27	Schering Corporation	Compounds that are erk inhibitors
JP5411152B2 (en) *	2008-02-22	2014-02-12	Ｍｓｄ株式会社	Novel aminopyridine derivatives having selective inhibition of Aurora A
EA019289B1 (en)	2008-04-21	2014-02-28	Тайджен Байотекнолоджи Ко., Лтд.	Aminopiridin, aminopirimidin and amino-1,3,5-triazine derivatives
WO2010011411A1 (en)	2008-05-27	2010-01-28	The Trustees Of Columbia University In The City Of New York	Systems, methods, and media for detecting network anomalies
TW201006830A (en) *	2008-06-11	2010-02-16	Astrazeneca Ab	Chemical compounds
EP2310372B1 (en)	2008-07-09	2012-05-23	Sanofi	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2318377B1 (en) *	2008-07-31	2013-08-21	Genentech, Inc.	Pyrimidine compounds, compositions and methods of use
JP2012501971A (en) *	2008-09-03	2012-01-26	バーテックスファーマシューティカルズインコーポレイテッド	Co-crystals and pharmaceutical formulations containing co-crystals
NZ603495A (en) *	2008-09-05	2014-05-30	Celgene Avilomics Res Inc	Algorithm for designing irreversible inhibitors
US8815885B2 (en)	2008-09-15	2014-08-26	The Regents Of The University Of California	Methods and compositions for modulating IRE1, SRC, and ABL activity
MX2011003447A (en) *	2008-09-30	2011-07-29	Astrazeneca Ab	Heterocyclic jak kinase inhibitors.
US8759362B2 (en) *	2008-10-24	2014-06-24	Purdue Pharma L.P.	Bicycloheteroaryl compounds and their use as TRPV1 ligands
WO2010056758A1 (en) *	2008-11-12	2010-05-20	Yangbo Feng	Quinazoline derivatives as kinase inhibitors
TW201021855A (en)	2008-11-13	2010-06-16	Taigen Biotechnology Co Ltd	Lyophilization formulation
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
PA8851101A1 (en)	2008-12-16	2010-07-27	Lilly Co Eli	AMINO PIRAZOL COMPOUND
WO2010070060A1 (en)	2008-12-19	2010-06-24	Nerviano Medical Sciences S.R.L.	Bicyclic pyrazoles as protein kinase inhibitors
AU2009330727B2 (en)	2008-12-22	2016-07-28	Millennium Pharmaceuticals, Inc.	Combination of Aurora kinase inhibitors and anti-CD20 antibodies
US8809343B2 (en)	2008-12-26	2014-08-19	Fudan University	Pyrimidine derivative, preparation method and use thereof
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
ES2456275T3 (en) *	2009-02-27	2014-04-21	Ambit Biosciences Corporation	JAK kinase modulator quinazoline derivatives and their use in methods
CA2660962A1 (en)	2009-03-31	2010-09-30	Astellas Pharma Inc.	Novel pharmaceutical composition for treatment of schizophrenia
US8399663B2 (en)	2009-04-03	2013-03-19	Astellas Pharma Inc.	Salt of 1,3,5-triazine-2,4,6-triamine derivative
JO3635B1 (en)	2009-05-18	2020-08-27	Millennium Pharm Inc	Solid pharmaceutical compositions and processes for their production
AU2010259002B2 (en) *	2009-06-08	2014-03-20	Nantbio, Inc.	Triazine derivatives and their therapeutical applications
EP2440052A4 (en) *	2009-06-08	2013-01-23	Abraxis Bioscience Llc	Triazine derivatives and their therapeutical applications
KR20120016676A (en) *	2009-06-09	2012-02-24	아브락시스 바이오사이언스, 엘엘씨	Ureidophenyl-substituted triazine derivatives and their therapeutic uses
JP2012529519A (en) *	2009-06-09	2012-11-22	アブラクシスバイオサイエンスリミテッドライアビリティーカンパニー	Styryl-triazine derivatives and their therapeutic applications
JP2012529517A (en) *	2009-06-09	2012-11-22	アブラクシスバイオサイエンスリミテッドライアビリティーカンパニー	Benzyl-substituted triazine derivatives and their therapeutic applications
KR101457027B1 (en)	2009-06-09	2014-10-31	캘리포니아 캐피탈 에쿼티, 엘엘씨	Triazine derivatives and their therapeutical applications
EP2443106A1 (en) *	2009-06-18	2012-04-25	Cellzome Limited	Heterocyclylaminopyrimidines as kinase inhibitors
TWI468402B (en) *	2009-07-31	2015-01-11	必治妥美雅史谷比公司	Compounds for the reduction of β-amyloid production
US8637525B2 (en)	2009-07-31	2014-01-28	Bristol-Myers Squibb Company	Compounds for the reduction of beta-amyloid production
ES2443016T3 (en)	2009-08-26	2014-02-17	Sanofi	New crystalline hydrates of heteroaromatic fluoroglycosides, pharmaceutical products comprising these compounds, and their use
MX339811B (en)	2009-09-16	2016-06-08	Celgene Avilomics Res Inc *	Protein kinase conjugates and inhibitors.
KR101923049B1 (en) *	2009-11-13	2018-11-28	인튜어티브 서지컬 오퍼레이션즈 인코포레이티드	End effector with redundant closing mechanisms
US9180127B2 (en)	2009-12-29	2015-11-10	Dana-Farber Cancer Institute, Inc.	Type II Raf kinase inhibitors
US20110269244A1 (en)	2009-12-30	2011-11-03	Petter Russell C	Ligand-directed covalent modification of protein
SA111320200B1 (en) *	2010-02-17	2014-02-16	ديبيوفارم اس ايه	Bicyclic Compounds and their Uses as Dual C-SRC / JAK Inhibitors
CN104031049A (en)	2010-02-19	2014-09-10	米伦纽姆医药公司	Crystalline Forms Of Aurora Kinase Inhibitor
WO2011107494A1 (en)	2010-03-03	2011-09-09	Sanofi	Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
EP2571359A4 (en) *	2010-05-20	2013-10-23	Merck Sharp & Dohme	NEW PROLYLCARBOXYPEPTIDASE INHIBITORS
MX2012013274A (en)	2010-05-21	2013-05-28	Chemilia Ab	Novel pyrimidine derivatives.
JP5713367B2 (en)	2010-06-04	2015-05-07	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Aminopyrimidine derivatives as LRRK2 modulators
EP2582709B1 (en)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
RU2611437C2 (en)	2010-07-29	2017-02-22	Оризон Дженомикс С.А.	Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
EP2611502A1 (en) *	2010-09-01	2013-07-10	Ambit Biosciences Corporation	Adenosine a3 receptor modulating compounds and methods of use thereof
MX2013002383A (en) *	2010-09-01	2013-07-05	Ambit Biosciences Corp	Hydrobromide salts of a pyrazolylaminoquinazoline.
AU2011296078B2 (en) *	2010-09-01	2015-06-18	Ambit Biosciences Corporation	An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
US20130225615A1 (en) *	2010-09-01	2013-08-29	Ambit Biosciences Corporation	2-cycloquinazoline derivatives and methods of use thereof
WO2012030944A2 (en) *	2010-09-01	2012-03-08	Ambit Biosciences Corporation	Quinoline and isoquinoline compounds and methods of use thereof
CA2810024A1 (en) *	2010-09-01	2012-03-08	Ambit Biosciences Corporation	Quinazoline compounds and methods of use thereof
WO2012030914A1 (en) *	2010-09-01	2012-03-08	Ambit Boisciences Corporation	4-azolylaminoquinazoline derivatives and methods of use thereof
WO2012059932A1 (en)	2010-11-01	2012-05-10	Aurigene Discovery Technologies Limited	2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
BR112013011600B1 (en)	2010-11-10	2022-01-11	Genentech, Inc	PYRAZOLE AMINOPYRIMIDINE DERIVATIVES, THEIR USE AND COMPOSITION INCLUDING THEM
EP2766349B1 (en)	2011-03-08	2016-06-01	Sanofi	Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683705B1 (en)	2011-03-08	2015-04-22	Sanofi	Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en)	2011-03-08	2014-09-30	Sanofi	Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683699B1 (en)	2011-03-08	2015-06-24	Sanofi	Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (en)	2011-03-08	2015-02-18	Sanofi	Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use
WO2012120057A1 (en)	2011-03-08	2012-09-13	Sanofi	Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8809324B2 (en)	2011-03-08	2014-08-19	Sanofi	Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
JP5886411B2 (en)	2011-03-24	2016-03-16	ノビガ・リサーチ・エービーＮｏｖｉｇａＲｅｓｅａｒｃｈＡＢ	New pyrimidine derivatives
CN104024248A (en) *	2011-08-25	2014-09-03	霍夫曼-拉罗奇有限公司	Serine/Threonine PAK1 Inhibitors
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
UA110259C2 (en) *	2011-09-22	2015-12-10	Пфайзер Інк.	PYROLOPYRIMIDINE AND PURINE DERIVATIVES
WO2013046136A1 (en)	2011-09-27	2013-04-04	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9382239B2 (en)	2011-11-17	2016-07-05	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-Jun-N-terminal kinase (JNK)
KR20140103972A (en)	2011-12-22	2014-08-27	에프. 호프만-라 로슈 아게	2,4-diamine-pyrimidine derivatives as serine/threonine kinase inhibitors
RU2014137448A (en) *	2012-02-17	2016-04-10	Эббви Инк.	DIAMINOPYRIMIDINES SUITABLE AS INHIBITORS OF RESPIRATORY-SYNCITIAL HUMAN VIRUS (RSV)
UY34632A (en)	2012-02-24	2013-05-31	Novartis Ag	OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
TWI485146B (en) *	2012-02-29	2015-05-21	Taiho Pharmaceutical Co Ltd	Novel piperidine compounds or salts thereof
SG11201405761WA (en)	2012-03-16	2014-10-30	Axikin Pharmaceuticals Inc	3,5-diaminopyrazole kinase inhibitors
US20130303519A1 (en)	2012-03-20	2013-11-14	Millennium Pharmaceuticals, Inc.	Methods of treating cancer using aurora kinase inhibitors
RS61664B1 (en)	2012-04-24	2021-04-29	Vertex Pharma	Dna-pk inhibitors
US9296725B2 (en) *	2012-05-24	2016-03-29	Cellzome Limited	Heterocyclyl pyrimidine analogues as TYK2 inhibitors
CA2880896C (en)	2012-06-26	2021-11-16	Del Mar Pharmaceuticals	Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
AU2013289615B2 (en) *	2012-07-10	2017-06-08	Ares Trading S.A.	Pyrimidine pyrazolyl derivatives
MX345435B (en) *	2012-09-19	2017-01-30	Taiho Pharmaceutical Co Ltd	Pharmaceutical composition for oral administration with improved elution and/or absorbency.
US9296733B2 (en)	2012-11-12	2016-03-29	Novartis Ag	Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103191120B (en) *	2012-12-31	2015-11-25	刘强	A kind of pyrimidine derivatives preparation prevent and/or treat and/or adjuvant therapy of tumors medicine in purposes
CN103202843B (en) *	2012-12-31	2015-04-29	刘强	Application of pyrimidine derivative in preparation of drugs capable of prevention and/or treatment and/or adjuvant therapy of cancers
CN103059002B (en) *	2012-12-31	2015-04-22	中山大学	Pyrimidine derivative with Aurora kinase inhibitory activity and preparation method and application thereof
CN103910716A (en) *	2013-01-07	2014-07-09	华东理工大学	2,4-disubstituted-cycloalkyl[d]pyrimidine compound and its use
HUE057527T2 (en)	2013-03-12	2022-05-28	Vertex Pharma	DNA-PK inhibitors
EA028033B1 (en)	2013-03-14	2017-09-29	Новартис Аг	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014145485A2 (en)	2013-03-15	2014-09-18	The Trustees Of Columbia University In The City Of New York	Map kinase modulators and uses thereof
JP6360881B2 (en)	2013-03-22	2018-07-18	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Combination of catalytic MTORC1 / 2 inhibitor and selective inhibitor of Aurora A kinase
WO2015003355A2 (en) *	2013-07-11	2015-01-15	Agios Pharmaceuticals, Inc.	Therapeutically active compounds and their methods of use
WO2015013579A1 (en)	2013-07-26	2015-01-29	Update Pharma Inc.	Compositions to improve the therapeutic benefit of bisantrene
WO2015028848A1 (en) *	2013-09-02	2015-03-05	Piramal Enterprises Limited	Bicyclic heterocyclic compounds as multi-kinase inhibitors
NZ631142A (en)	2013-09-18	2016-03-31	Axikin Pharmaceuticals Inc	Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
HRP20181841T1 (en)	2013-10-17	2019-01-11	Vertex Pharmaceuticals Incorporated	SUCRISTALS (S) -N-METHYL-8- (1 - ((2′-METHYL- [4,5′-BIPYRIMIDIN] -6-IL) AMINO) PROPAN-2-IL) QUINOLINE-4-CARBOXAMIDE AND ITS DEUTERATED DERIVATIVES AS A DNA-PK INHIBITOR
AU2014337044A1 (en)	2013-10-18	2016-05-05	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3057955B1 (en)	2013-10-18	2018-04-11	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
LT3089971T (en)	2014-01-01	2020-10-12	Medivation Technologies Llc	Compounds and methods of use
US10258585B2 (en)	2014-03-13	2019-04-16	Neuroderm, Ltd.	DOPA decarboxylase inhibitor compositions
EP3116475B1 (en)	2014-03-13	2020-11-04	Neuroderm Ltd	Dopa decarboxylase inhibitor compositions
EP3122729A4 (en)	2014-03-28	2017-11-15	Calitor Sciences, LLC	Substituted heteroaryl compounds and methods of use
RS60878B1 (en)	2014-04-04	2020-11-30	Iomet Pharma Ltd	Indole derivatives for use in medicine
US20170165230A1 (en)	2014-04-09	2017-06-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
CN105367555B (en) *	2014-08-07	2019-06-25	广东东阳光药业有限公司	Substituted heteroaryl compound and combinations thereof and purposes
SI3604294T1 (en)	2014-10-13	2021-08-31	Yuhan Corporation	Compounds and compositions for modulating egfr mutant kinase activities
EA032473B1 (en)	2014-12-23	2019-05-31	Аксикин Фармасьютикалз, Инк.	3,5-diaminopyrazole kinase inhibitors
US10870651B2 (en)	2014-12-23	2020-12-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016123627A1 (en) *	2015-01-30	2016-08-04	Vanderbilt University	Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction
US10550121B2 (en)	2015-03-27	2020-02-04	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
CA2982890C (en)	2015-04-17	2023-08-22	Ludwig Institute For Cancer Research Ltd	Plk4 inhibitors
MX378963B (en)	2015-05-28	2025-03-10	Theravance Biopharma R&D Ip Llc	NAPHTHYRIDINE COMPOUNDS AS JAK KINASE INHIBITORS.
JP2018135268A (en) *	2015-06-05	2018-08-30	大日本住友製薬株式会社	Novel heteroaryl amino-3-pyrazole derivative and pharmacologically acceptable salt thereof
EP3324976A4 (en)	2015-07-21	2019-03-27	Millennium Pharmaceuticals, Inc.	Administration of aurora kinase inhibitor and chemotherapeutic agents
WO2017044858A2 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
EP3347097B1 (en)	2015-09-11	2021-02-24	Sunshine Lake Pharma Co., Ltd.	Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
PL3386511T3 (en) *	2015-12-10	2021-11-08	Ptc Therapeutics, Inc.	Methods for treating huntington's disease
CN105399695B (en) *	2015-12-11	2019-04-19	浙江大学	Triazine compound and its preparation method and use
CN105384702B (en) *	2015-12-11	2018-04-10	浙江大学	Three substitution s-triazine compounds and preparation method thereof
CN105503754B (en) *	2015-12-11	2017-11-17	浙江大学	The triazine of 2 amino, 4 benzyl, 6 morpholine 1,3,5 and its preparation and application
US10894784B2 (en)	2015-12-18	2021-01-19	Bayer Pharma Aktiengesellschaft	Heteroarylbenzimidazole compounds
EP3430000B1 (en)	2016-03-14	2022-12-28	Afferent Pharmaceuticals Inc.	Pyrimidines and variants thereof, and uses therefor
CN108779119B (en)	2016-03-25	2022-02-08	传入制药公司	Pyrimidines and variants thereof, and uses thereof
US10028960B2 (en)	2016-04-28	2018-07-24	Theravance Biopharma R&D Ip, Llc	Pyrimidine compounds as JAK kinase inhibitors
WO2017207534A1 (en)	2016-06-03	2017-12-07	Bayer Pharma Aktiengesellschaft	Substituted heteroarylbenzimidazole compounds
JP2019529475A (en)	2016-09-27	2019-10-17	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Method for treating cancer using a combination of a DNA damaging agent and a DNA-PK inhibitor
US10858319B2 (en)	2016-10-03	2020-12-08	Iomet Pharma Ltd.	Indole derivatives for use in medicine
US10968227B2 (en) *	2016-11-08	2021-04-06	Vanderbilt University	Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
CN108239071B (en) *	2016-12-27	2020-12-04	沈阳药科大学	Amide and thioamide derivatives and preparation method and application thereof
FR3064275B1 (en)	2017-03-21	2019-06-07	Arkema France	METHOD FOR HEATING AND / OR AIR CONDITIONING A VEHICLE
JP7179777B2 (en)	2017-05-30	2022-11-29	ビーエーエスエフソシエタス・ヨーロピア	pyridine compounds and pyrazine compounds
KR20200033249A (en)	2017-06-05	2020-03-27	피티씨 테라퓨틱스, 인크.	Huntington's Disease Treatment Compound
US11395822B2 (en)	2017-06-28	2022-07-26	Ptc Therapeutics, Inc.	Methods for treating Huntington's disease
CN111182898B (en)	2017-06-28	2024-04-16	Ptc医疗公司	Methods for treating Huntington's disease
CN110582491B (en)	2017-06-30	2023-09-29	北京泰德制药股份有限公司	Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor
JP2020525525A (en) *	2017-06-30	2020-08-27	ベイジンタイドファーマシューティカルカンパニーリミテッドＢｅｉｊｉｎｇＴｉｄｅＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	RHO-related protein kinase inhibitor, pharmaceutical composition containing RHO-related protein kinase inhibitor, preparation method and use of the pharmaceutical composition
EP3647311B1 (en)	2017-06-30	2023-11-01	Beijing Tide Pharmaceutical Co., Ltd.	Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof
WO2019046163A1 (en) *	2017-08-28	2019-03-07	Zhihong Chen	Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
WO2019046316A1 (en) *	2017-08-28	2019-03-07	Acurastem Inc.	Pikfyve kinase inhibitors
EA202091016A1 (en)	2017-10-27	2020-07-17	ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи	PYRIMIDINE COMPOUND AS A JAK KINASE INHIBITOR
MX2020004536A (en) *	2017-11-23	2020-08-03	Biomed X Gmbh	Pyrimidine derivatives as tropomyosin receptor kinase a (trka) inhibitors.
US11612604B2 (en)	2017-12-06	2023-03-28	Ludwig Institute For Cancer Research Ltd	Methods of treating cancer with PLK4 inhibitors
EP3765459A1 (en)	2018-03-13	2021-01-20	Shire Human Genetic Therapies, Inc.	Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
EA202092001A1 (en)	2018-03-27	2021-01-29	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	COMPOUNDS FOR TREATMENT OF GENTINGTON'S DISEASE
CA3099763A1 (en)	2018-06-25	2020-01-02	Dana-Farber Cancer Institute, Inc.	Taire family kinase inhibitors and uses thereof
SG11202012674PA (en)	2018-06-27	2021-01-28	Ptc Therapeutics Inc	Heterocyclic and heteroaryl compounds for treating huntington's disease
AU2019294482B2 (en)	2018-06-27	2022-09-01	Ptc Therapeutics, Inc.	Heteroaryl compounds for treating Huntington's disease
EP3814360B8 (en)	2018-06-27	2024-11-06	PTC Therapeutics, Inc.	Heteroaryl compounds for treating huntington's disease
MX2021006283A (en) *	2018-11-30	2021-10-22	Jiangsu Hansoh Pharmaceutical Group Co Ltd	Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof.
JP7660063B2 (en)	2018-12-28	2025-04-10	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	Inhibitors of cyclin-dependent kinase 7 and their uses
ES2994097T3 (en)	2019-04-24	2025-01-17	Theravance Biopharma R&D Ip Llc	Pyrimidine jak inhibitors for the treatment of skin diseases
JP7470713B2 (en)	2019-04-24	2024-04-18	セラヴァンスバイオファーマアール＆ディーアイピー，エルエルシー	Ester and Carbonate Pyrimidine Compounds as JAK Kinase Inhibitors - Patent application
EP4007757B1 (en) *	2019-08-01	2025-09-10	Sperogenix Therapeutics Limited	Heterocyclic compounds as kinase inhibitor and uses thereof
US11787796B2 (en)	2019-09-18	2023-10-17	Takeda Pharmaceutical Company Limited	Plasma Kallikrein inhibitors and uses thereof
JP7695232B2 (en)	2019-09-18	2025-06-18	武田薬品工業株式会社	Heteroaryl plasma kallikrein inhibitors
CN110483493A (en) *	2019-09-19	2019-11-22	广东工业大学	A kind of diazole analog derivative and its preparation method and application
AU2021207804A1 (en)	2020-01-13	2022-09-01	Verge Analytics, Inc.	Substituted pyrazolo-pyrimidines and uses thereof
US11213502B1 (en)	2020-11-17	2022-01-04	Neuroderm, Ltd.	Method for treatment of parkinson's disease
US11844754B2 (en)	2020-11-17	2023-12-19	Neuroderm, Ltd.	Methods for treatment of Parkinson's disease
US11331293B1 (en)	2020-11-17	2022-05-17	Neuroderm, Ltd.	Method for treatment of Parkinson's disease
TW202237119A (en)	2020-12-10	2022-10-01	美商住友製藥腫瘤公司	Alk-5 inhibitors and uses thereof
US20240199613A1 (en) *	2021-03-17	2024-06-20	Takeda Pharmaceutical Company Limited	Polycyclic inhibitors of plasma kallikrein
JP2024511012A (en) *	2021-03-24	2024-03-12	アトスセラピューティクス，インコーポレイテッド	Small molecules for the treatment of kinase-related diseases
WO2022204721A1 (en) *	2021-03-26	2022-09-29	Sumitomo Pharma Oncology, Inc.	Alk-5 inhibitors and uses thereof
US20240270722A1 (en)	2021-05-11	2024-08-15	Oric Pharmaceuticals, Inc.	Polo like kinase 4 inhibitors
TW202317574A (en)	2021-06-28	2023-05-01	美商纜圖藥品公司	Cdk2 inhibitors
KR102692529B1 (en) *	2021-07-01	2024-08-08	한국원자력의학원	Pharmaceutical Composition For Preventing or Treating Cancer Targeting MASTL-PP2A
CN116354938B (en) *	2021-12-28	2024-02-20	沈阳药科大学	Preparation method and application of quinazoline derivatives and analogues thereof
CN114276302B (en) *	2022-01-11	2023-07-25	山东百启生物医药有限公司	Method for preparing 2, 4-diaminoquinazoline derivative
CN116813595B (en) *	2022-03-28	2025-07-18	上海医药工业研究院有限公司	Quinazoline derivative, preparation method thereof, pharmaceutical composition and application
WO2024003773A1 (en)	2022-07-01	2024-01-04	Pfizer Inc.	2,7-naphthyridine compounds as mastl inhibitors
CN115403568B (en) *	2022-09-21	2023-09-29	中山大学	Quinazoline Aurora A covalent inhibitor and preparation method and application thereof
CN117736198A (en) *	2022-09-21	2024-03-22	科辉智药生物科技(深圳)有限公司	Macrocyclic nitrogen crown ether compounds and their use as protein kinase inhibitors
EP4669648A2 (en) *	2023-02-23	2025-12-31	Accutar Biotechnology Inc.	Novel macrocyclic aminopyrazol compounds as CDK2 inhibitors
US12161612B2 (en)	2023-04-14	2024-12-10	Neuroderm, Ltd.	Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US18436A (en) *		1857-10-20		And saml
US3133081A (en) *		1964-05-12		J-aminoindazole derivatives
US2585906A (en)		1952-02-12		Quaternary salts of pyrimdjines
US3935183A (en) *	1970-01-26	1976-01-27	Imperial Chemical Industries Limited	Indazole-azo phenyl compounds
BE754242A (en) *	1970-07-15	1971-02-01	Geigy Ag J R	DIAMINO-S-TRIAZINES AND DINITRO-S-TRIAZINES
US3755332A (en) *	1971-07-01	1973-08-28	Ciba Geigy Corp	Substituted 4 indazolaminoquinolines
US3998951A (en) *	1974-03-13	1976-12-21	Fmc Corporation	Substituted 2-arylquinazolines as fungicides
DE2458965C3 (en)	1974-12-13	1979-10-11	Bayer Ag, 5090 Leverkusen	3-Amino-indazole-N-carboxylic acid derivatives, process for their preparation and pharmaceuticals containing them
MA18829A1 (en)	1979-05-18	1980-12-31	Ciba Geigy Ag	PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR THERAPEUTIC USE
DOP1981004033A (en) *	1980-12-23	1990-12-29	Ciba Geigy Ag	PROCEDURE TO PROTECT CROP PLANTS FROM PHYTOTOXIC ACTION OF HERBICIDES.
SE8102193L (en) *	1981-04-06	1982-10-07	Pharmacia Ab	THERAPEUTIC ACTIVE ORGANIC ASSOCIATION AND ITS USE
SE8102194L (en) *	1981-04-06	1982-10-07	Pharmacia Ab	THERAPEUTIC ACTIVE ORGANIC ASSOCIATION AND PHARMACEUTICAL PREPARATION INCLUDING THIS
JPS58124773A (en)	1982-01-20	1983-07-25	Mitsui Toatsu Chem Inc	5-Methylthiopyrimidine derivatives, their production methods, and agricultural and horticultural fungicides
EP0136976A3 (en)	1983-08-23	1985-05-15	Ciba-Geigy Ag	Use of phenyl pyrimidines as plant regulators
DE3725638A1 (en)	1987-08-03	1989-02-16	Bayer Ag	NEW ARYLOXY (OR THIO) AMINOPYRIMIDINE
JPH0532662A (en)	1990-11-09	1993-02-09	Nissan Chem Ind Ltd	Substituted pyrazole derivative and agricultural and horticultural fungicide
US5714493A (en) *	1991-05-10	1998-02-03	Rhone-Poulenc Rorer Pharmaceuticals, Inc.	Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en)	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5597920A (en)	1992-04-30	1997-01-28	Neurogen Corporation	Gabaa receptor subtypes and methods for screening drug compounds using imidazoquinoxalines and pyrrolopyrimidines to bind to gabaa receptor subtypes
JPH0665237A (en)	1992-05-07	1994-03-08	Nissan Chem Ind Ltd	Substituted pyrazole derivative and germicide for agriculture and horticulture
ATE325113T1 (en)	1993-10-01	2006-06-15	Novartis Pharma Gmbh	PHARMACOLOGICALLY ACTIVE PYRIMIDINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
AU700964B2 (en)	1994-11-10	1999-01-14	Cor Therapeutics, Inc.	Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
IL117659A (en) *	1995-04-13	2000-12-06	Dainippon Pharmaceutical Co	Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same
WO1997009325A1 (en)	1995-09-01	1997-03-13	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en)	1995-09-01	1999-08-10	Signal Pharmaceuticals, Inc.	Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
US6716575B2 (en) *	1995-12-18	2004-04-06	Sugen, Inc.	Diagnosis and treatment of AUR1 and/or AUR2 related disorders
PT912559E (en)	1996-07-13	2003-03-31	Glaxo Group Ltd	HETEROCYCLIC COMPOUNDS FUSED AS PROTEIN INHIBITORS TYROSINE KINASE
JPH10130150A (en)	1996-09-05	1998-05-19	Dainippon Pharmaceut Co Ltd	Pharmaceuticals consisting of acetic acid amide derivatives
GB9619284D0 (en) *	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
US6251911B1 (en)	1996-10-02	2001-06-26	Novartis Ag	Pyrimidine derivatives and processes for the preparation thereof
CA2268098A1 (en)	1996-10-11	1998-04-23	Warner-Lambert Company	Aspartate ester inhibitors of interleukin-1.beta. converting enzyme
DE19710435A1 (en) *	1997-03-13	1998-09-17	Hoechst Ag	Use of pyrimidine derivatives for the prevention of cancer alone or in combination with other therapeutic measures
AU741203B2 (en)	1997-10-10	2001-11-22	Cytovia, Inc.	Dipeptide apoptosis inhibitors and the use thereof
US6267952B1 (en) *	1998-01-09	2001-07-31	Geltex Pharmaceuticals, Inc.	Lipase inhibiting polymers
JP2000026421A (en)	1998-01-29	2000-01-25	Kumiai Chem Ind Co Ltd	Diaryl sulfide derivative and pest controlling agent
US6200977B1 (en)	1998-02-17	2001-03-13	Tularik Inc.	Pyrimidine derivatives
DE69925268T2 (en)	1998-03-16	2006-03-23	Cytovia, Inc., San Diego	Dipeptide caspase inhibitors and their use
TR200003513T2 (en)	1998-06-02	2001-06-21	Osi Pharmaceuticals, Inc.	Pirolo [2,3d] Pyrimidine compositions and uses
JP4533534B2 (en)	1998-06-19	2010-09-01	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	Inhibitor of glycogen synthase kinase 3
WO2000003901A1 (en) *	1998-07-16	2000-01-27	Continental Teves Ag & Co. Ohg	Method and device for detecting the critical driving states in vehicles which are being driven
CA2339188A1 (en) *	1998-08-21	2000-03-02	Dupont Pharmaceuticals Company	Isoxazolo¬4,5-d\|pyrimidines as crf antagonists
US6184226B1 (en)	1998-08-28	2001-02-06	Scios Inc.	Quinazoline derivatives as inhibitors of P-38 α
DE69925141T2 (en) *	1998-10-08	2006-04-27	Astrazeneca Ab	CHINAZOLINE DERIVATIVES
GB9828640D0 (en)	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
BR9916896A (en)	1999-01-13	2001-11-20	Warner Lambert Co	Diaryl amines substituted with 1-heterocycle
GB9905075D0 (en) *	1999-03-06	1999-04-28	Zeneca Ltd	Chemical compounds
AU766081B2 (en)	1999-03-30	2003-10-09	Novartis Ag	Phthalazine derivatives for treating inflammatory diseases
AU781849C (en) *	1999-06-17	2006-03-02	Synta Pharmaceuticals Corp.	Inhibitors of IL-12 production
GB9914258D0 (en) *	1999-06-18	1999-08-18	Celltech Therapeutics Ltd	Chemical compounds
CZ2002534A3 (en)	1999-08-13	2002-07-17	Vertex Pharmaceuticals Incorporated	Inhibitors of protein-kinases, pharmaceutical preparations in which they are comprised as well as their use
ATE396978T1 (en)	1999-10-07	2008-06-15	Amgen Inc	TRIAZINE KINASE INHIBITORS
HUP0203300A3 (en)	1999-11-30	2003-10-28	Pfizer Prod Inc	2,4-diaminopyrimidine compounds useful as immunosuppressants, pharmaceutical compositions containing them and their use
WO2001039777A1 (en)	1999-12-02	2001-06-07	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
MY125768A (en)	1999-12-15	2006-08-30	Bristol Myers Squibb Co	N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US6376489B1 (en)	1999-12-23	2002-04-23	Icos Corporation	Cyclic AMP-specific phosphodiesterase inhibitors
AU2735201A (en)	1999-12-28	2001-07-09	Pharmacopeia, Inc.	Pyrimidine and triazine kinase inhibitors
US20020065270A1 (en)	1999-12-28	2002-05-30	Moriarty Kevin Joseph	N-heterocyclic inhibitors of TNF-alpha expression
CN1362953A (en) *	2000-02-05	2002-08-07	沃泰克斯药物股份有限公司	Pyrazole compositions useful as inhibitors of ERK
AU2001237041B9 (en) *	2000-02-17	2005-07-28	Amgen Inc.	Kinase inhibitors
GB0004890D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004887D0 (en) *	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
ATE297946T1 (en)	2000-04-03	2005-07-15	Vertex Pharma	INHIBITORS OF SERINE PROTEASES, SPECIFICALLY THE HEPATITIS C VIRUS NS3 PROTEASE
CA2398446A1 (en)	2000-04-18	2001-10-25	Agouron Pharmaceuticals, Inc.	Pyrazoles for inhibiting protein kinases
JP3890184B2 (en) *	2000-05-15	2007-03-07	Ｎｅｃパーソナルプロダクツ株式会社	Power supply device, power control method thereof, and information processing apparatus
ES2305081T3 (en) *	2000-06-28	2008-11-01	Astrazeneca Ab	SUBSTITUTED QUINOZOLINE DERIVATIVES AND ITS USE AS INHIBITORS.
IL153670A0 (en)	2000-07-21	2003-07-06	Schering Corp	Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
NZ523656A (en)	2000-08-31	2004-11-26	Pfizer Prod Inc	Pyrazole derivatives and their use as protein kinase inhibitors
US7473691B2 (en) *	2000-09-15	2009-01-06	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
NZ525016A (en) *	2000-09-15	2004-10-29	Vertex Pharma	Isoxazoles and their use as inhibitors of ERK
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) *	2000-09-15	2003-09-02	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (en) *	2000-09-15	2006-11-22	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) *	2000-09-15	2003-08-26	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
BR0114020A (en)	2000-09-20	2003-07-22	Merck Patent Gmbh	4-amino-quinazolines
US6641579B1 (en) *	2000-09-29	2003-11-04	Spectrasonics Imaging, Inc.	Apparatus and method for ablating cardiac tissue
US6716851B2 (en) *	2000-12-12	2004-04-06	Cytovia, Inc.	Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
WO2002047690A1 (en)	2000-12-12	2002-06-20	Cytovia, Inc.	Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
DE10061863A1 (en) *	2000-12-12	2002-06-13	Basf Ag	Preparation of triethylenediamine, useful for making pharmaceuticals and polymers, by reacting ethylenediamine over specific zeolite catalyst
CA2432222C (en) *	2000-12-21	2008-07-29	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) *	2001-02-09	2007-07-31	Vertex Pharma	Heterocyclic inhibitiors of erk2 and uses thereof
DE60223790D1 (en) *	2001-03-29	2008-01-10	Vertex Pharma	HEMMER OF C-JUN TERMINAL KINASE (JNK) AND OTHER PROTEIN KINASE
AU2002338642A1 (en) *	2001-04-13	2002-10-28	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
US20030096813A1 (en) *	2001-04-20	2003-05-22	Jingrong Cao	Compositions useful as inhibitors of GSK-3
WO2002092573A2 (en) *	2001-05-16	2002-11-21	Vertex Pharmaceuticals Incorporated	Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases
CA2450769A1 (en) *	2001-06-15	2002-12-27	Vertex Pharmaceuticals Incorporated	5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors
JP4342937B2 (en) *	2001-07-03	2009-10-14	バーテックスファーマシューティカルズインコーポレイテッド	Isoxazole pyrimidines as inhibitors of Src and Lck protein kinases
WO2003026666A1 (en) *	2001-09-26	2003-04-03	Bayer Pharmaceuticals Corporation	2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
US6569499B2 (en) *	2001-10-02	2003-05-27	Xerox Corporation	Apparatus and method for coating photoreceptor substrates
MXPA04005510A (en) *	2001-12-07	2006-02-24	Vertex Pharma	Pyrimidine-based compounds useful as gsk-3 inhibitors.
WO2003077921A1 (en) *	2002-03-15	2003-09-25	Vertex Pharmaceuticals, Inc.	Azinylaminoazoles as inhibitors of protein kinases
US7179826B2 (en) *	2002-03-15	2007-02-20	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
EP1485376B1 (en) *	2002-03-15	2007-06-27	Vertex Pharmaceuticals Incorporated	Compositions useful as inhibitors of protein kinases
US20040009981A1 (en) *	2002-03-15	2004-01-15	David Bebbington	Compositions useful as inhibitors of protein kinases
US20030207873A1 (en) *	2002-04-10	2003-11-06	Edmund Harrington	Inhibitors of Src and other protein kinases
AU2003237121A1 (en) *	2002-04-26	2003-11-10	Vertex Pharmaceuticals Incorporated	Pyrrole derivatives as inhibitors of erk2 and uses thereof
MY141867A (en) *	2002-06-20	2010-07-16	Vertex Pharma	Substituted pyrimidines useful as protein kinase inhibitors
CA2491895C (en) *	2002-07-09	2011-01-18	Vertex Pharmaceuticals Incorporated	Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
CN101037438A (en)	2002-08-02	2007-09-19	沃泰克斯药物股份有限公司	Compositions useful as inhibitors of GSK-3
NZ567241A (en)	2005-09-30	2010-08-27	Miikana Therapeutics Inc	Substituted pyrazole compounds
DE602007007985D1 (en)	2006-12-19	2010-09-02	Vertex Pharma	AS INHIBITORS OF PROTEIN KINASES SUITABLE AMINO-PRIMIDINES

2001
- 2001-12-19 CA CA002432222A patent/CA2432222C/en not_active Expired - Fee Related
- 2001-12-19 ES ES01994510T patent/ES2265452T3/en not_active Expired - Lifetime
- 2001-12-19 EP EP01994323A patent/EP1353916B1/en not_active Expired - Lifetime
- 2001-12-19 US US10/027,001 patent/US6653301B2/en not_active Expired - Fee Related
- 2001-12-19 CN CNB01822105XA patent/CN100406454C/en not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005609A patent/MXPA03005609A/en active IP Right Grant
- 2001-12-19 DE DE60119775T patent/DE60119775T2/en not_active Expired - Lifetime
- 2001-12-19 US US10/025,164 patent/US6664247B2/en not_active Expired - Fee Related
- 2001-12-19 ES ES06011799T patent/ES2375491T3/en not_active Expired - Lifetime
- 2001-12-19 DK DK01273861T patent/DK1355905T3/en active
- 2001-12-19 NZ NZ526470A patent/NZ526470A/en not_active IP Right Cessation
- 2001-12-19 EP EP01993360A patent/EP1345926B1/en not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/049140 patent/WO2002050065A2/en not_active Ceased
- 2001-12-19 KR KR1020037008385A patent/KR100889246B1/en not_active Expired - Fee Related
- 2001-12-19 MX MXPA03005606A patent/MXPA03005606A/en active IP Right Grant
- 2001-12-19 KR KR1020037008397A patent/KR100947185B1/en not_active Expired - Fee Related
- 2001-12-19 PT PT01273861T patent/PT1355905E/en unknown
- 2001-12-19 NZ NZ526469A patent/NZ526469A/en not_active IP Right Cessation
- 2001-12-19 US US10/026,992 patent/US7625913B2/en not_active Expired - Fee Related
- 2001-12-19 CN CNB01822136XA patent/CN100340555C/en not_active Expired - Fee Related
- 2001-12-19 US US10/026,966 patent/US20030105090A1/en not_active Abandoned
- 2001-12-19 AT AT01271061T patent/ATE327989T1/en active
- 2001-12-19 IL IL15636801A patent/IL156368A0/en not_active IP Right Cessation
- 2001-12-19 WO PCT/US2001/049139 patent/WO2002066461A1/en not_active Ceased
- 2001-12-19 US US10/026,967 patent/US6989385B2/en not_active Expired - Fee Related
- 2001-12-19 ES ES01985059T patent/ES2265446T3/en not_active Expired - Lifetime
- 2001-12-19 DK DK01271061T patent/DK1345922T3/en active
- 2001-12-19 JP JP2002563142A patent/JP4160395B2/en not_active Expired - Fee Related
- 2001-12-19 AP APAP/P/2003/002825A patent/AP2003002825A0/en unknown
- 2001-12-19 PT PT01994323T patent/PT1353916E/en unknown
- 2001-12-19 JP JP2002559413A patent/JP4160392B2/en not_active Expired - Fee Related
- 2001-12-19 DE DE60123283T patent/DE60123283T2/en not_active Expired - Lifetime
- 2001-12-19 KR KR10-2003-7008415A patent/KR20030061858A/en not_active Abandoned
- 2001-12-19 HU HU0400641A patent/HUP0400641A3/en unknown
- 2001-12-19 AU AU2001297619A patent/AU2001297619B2/en not_active Ceased
- 2001-12-19 IL IL15636901A patent/IL156369A0/en active IP Right Grant
- 2001-12-19 BR BR0116493-7A patent/BR0116493A/en not_active IP Right Cessation
- 2001-12-19 ES ES01994323T patent/ES2272567T3/en not_active Expired - Lifetime
- 2001-12-19 US US10/026,975 patent/US6653300B2/en not_active Expired - Fee Related
- 2001-12-19 IL IL15640701A patent/IL156407A0/en not_active IP Right Cessation
- 2001-12-19 MX MXPA03005605A patent/MXPA03005605A/en active IP Right Grant
- 2001-12-19 CN CN2011101042845A patent/CN102250071A/en active Pending
- 2001-12-19 PL PL363244A patent/PL210414B1/en not_active IP Right Cessation
- 2001-12-19 PT PT01271061T patent/PT1345922E/en unknown
- 2001-12-19 CA CA002432223A patent/CA2432223C/en not_active Expired - Fee Related
- 2001-12-19 AU AU2002255452A patent/AU2002255452B2/en not_active Ceased
- 2001-12-19 MX MXPA03005607A patent/MXPA03005607A/en active IP Right Grant
- 2001-12-19 NZ NZ526472A patent/NZ526472A/en not_active IP Right Cessation
- 2001-12-19 EP EP01271061A patent/EP1345922B1/en not_active Expired - Lifetime
- 2001-12-19 JP JP2002565976A patent/JP2004518743A/en active Pending
- 2001-12-19 HU HU0400842A patent/HUP0400842A2/en unknown
- 2001-12-19 DE DE60126828T patent/DE60126828T2/en not_active Expired - Lifetime
- 2001-12-19 CA CA002432799A patent/CA2432799C/en not_active Expired - Fee Related
- 2001-12-19 KR KR1020037008409A patent/KR100909665B1/en not_active Expired - Fee Related
- 2001-12-19 AP APAP/P/2003/002816A patent/AP1588A/en active
- 2001-12-19 ES ES01273861T patent/ES2280313T3/en not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/051031 patent/WO2002062789A1/en not_active Ceased
- 2001-12-19 JP JP2002567928A patent/JP4234435B2/en not_active Expired - Fee Related
- 2001-12-19 AT AT01273861T patent/ATE354573T1/en active
- 2001-12-19 AT AT01985059T patent/ATE326460T1/en active
- 2001-12-19 EP EP06011799A patent/EP1702920B1/en not_active Expired - Lifetime
- 2001-12-19 WO PCT/US2001/049401 patent/WO2002057259A2/en not_active Ceased
- 2001-12-19 DK DK01994323T patent/DK1353916T3/en active
- 2001-12-19 WO PCT/US2001/050312 patent/WO2002068415A1/en not_active Ceased
- 2001-12-19 EP EP01994510A patent/EP1345927B1/en not_active Expired - Lifetime
- 2001-12-19 AT AT01993360T patent/ATE326461T1/en active
- 2001-12-19 NZ NZ526471A patent/NZ526471A/en not_active IP Right Cessation
- 2001-12-19 HU HU0400638A patent/HUP0400638A2/en unknown
- 2001-12-19 EP EP10184271A patent/EP2264028A1/en not_active Withdrawn
- 2001-12-19 SI SI200130656T patent/SI1353916T1/en unknown
- 2001-12-19 IL IL15640801A patent/IL156408A0/en unknown
- 2001-12-19 ES ES01993360T patent/ES2265450T3/en not_active Expired - Lifetime
- 2001-12-19 IL IL15638901A patent/IL156389A0/en active IP Right Grant
- 2001-12-19 CN CNB018221025A patent/CN100436452C/en not_active Expired - Fee Related
- 2001-12-19 AU AU2002234047A patent/AU2002234047A1/en not_active Abandoned
- 2001-12-19 HU HU0400639A patent/HUP0400639A3/en unknown
- 2001-12-19 KR KR1020037008427A patent/KR100875091B1/en not_active Expired - Fee Related
- 2001-12-19 HU HU0400908A patent/HUP0400908A3/en unknown
- 2001-12-19 ES ES01271061T patent/ES2266095T3/en not_active Expired - Lifetime
- 2001-12-19 JP JP2002557938A patent/JP4210520B2/en not_active Expired - Fee Related
- 2001-12-19 NZ NZ526473A patent/NZ526473A/en not_active IP Right Cessation
- 2001-12-19 NZ NZ526468A patent/NZ526468A/en not_active IP Right Cessation
- 2001-12-19 MX MXPA03005608A patent/MXPA03005608A/en not_active Application Discontinuation
- 2001-12-19 CN CNA018221033A patent/CN1486310A/en active Pending
- 2001-12-19 JP JP2002551561A patent/JP4160389B2/en not_active Expired - Fee Related
- 2001-12-19 AT AT06011799T patent/ATE528303T1/en not_active IP Right Cessation
- 2001-12-19 WO PCT/US2001/051120 patent/WO2002059111A2/en not_active Ceased
- 2001-12-19 EP EP01273861A patent/EP1355905B1/en not_active Expired - Lifetime
- 2001-12-19 BR BR0116411-2A patent/BR0116411A/en not_active IP Right Cessation
- 2001-12-19 CN CNB018221351A patent/CN100408573C/en not_active Expired - Fee Related
- 2001-12-19 CA CA2432303A patent/CA2432303C/en not_active Expired - Fee Related
- 2001-12-19 RU RU2003122209/04A patent/RU2355688C2/en not_active IP Right Cessation
- 2001-12-19 AT AT01994323T patent/ATE340172T1/en active
- 2001-12-19 EP EP01985059A patent/EP1345925B1/en not_active Expired - Lifetime
- 2001-12-19 CA CA002432131A patent/CA2432131C/en not_active Expired - Fee Related
- 2001-12-19 DE DE60120219T patent/DE60120219T2/en not_active Expired - Lifetime
- 2001-12-19 DE DE60119774T patent/DE60119774T2/en not_active Expired - Lifetime
- 2001-12-19 PL PL363246A patent/PL210066B1/en unknown
- 2001-12-19 KR KR1020037008387A patent/KR100843114B1/en not_active Expired - Fee Related
- 2001-12-19 AT AT01994510T patent/ATE326462T1/en active
- 2001-12-19 MX MXPA03005610A patent/MXPA03005610A/en active IP Right Grant
- 2001-12-19 DE DE60119776T patent/DE60119776T2/en not_active Expired - Lifetime
- 2001-12-19 SI SI200130722T patent/SI1355905T1/en unknown
- 2001-12-19 CA CA002432129A patent/CA2432129C/en not_active Expired - Fee Related
- 2001-12-20 AU AU2002246754A patent/AU2002246754B2/en not_active Ceased
- 2001-12-20 AR ARP010105962A patent/AR042169A1/en active IP Right Grant
- 2001-12-20 JP JP2002559414A patent/JP2004517927A/en active Pending
- 2001-12-20 DE DE60119777T patent/DE60119777T2/en not_active Expired - Lifetime
- 2001-12-20 KR KR10-2003-7008364A patent/KR20030061463A/en not_active Abandoned
- 2001-12-20 DE DE60126658T patent/DE60126658T2/en not_active Expired - Lifetime
- 2001-12-20 CA CA002432132A patent/CA2432132C/en not_active Expired - Fee Related
- 2001-12-20 AT AT01994347T patent/ATE326463T1/en not_active IP Right Cessation
- 2001-12-20 US US10/034,019 patent/US6727251B2/en not_active Expired - Fee Related
- 2001-12-20 US US10/034,683 patent/US6656939B2/en not_active Expired - Fee Related
- 2001-12-20 AR ARP010105960A patent/AR042397A1/en active IP Right Grant
- 2001-12-20 AU AU2002231166A patent/AU2002231166B2/en not_active Ceased
- 2001-12-20 MX MXPA03005611A patent/MXPA03005611A/en unknown
- 2001-12-20 NZ NZ526474A patent/NZ526474A/en unknown
- 2001-12-20 AR ARP010105961A patent/AR042398A1/en unknown
- 2001-12-20 JP JP2002551562A patent/JP2004516292A/en active Pending
- 2001-12-20 WO PCT/US2001/049594 patent/WO2002059112A2/en not_active Ceased
- 2001-12-20 MX MXPA03005612A patent/MXPA03005612A/en not_active Application Discontinuation
- 2001-12-20 AT AT01991439T patent/ATE353890T1/en not_active IP Right Cessation
- 2001-12-20 EP EP01994347A patent/EP1345929B1/en not_active Expired - Lifetime
- 2001-12-20 AU AU3116602A patent/AU3116602A/en active Pending
- 2001-12-20 NZ NZ526475A patent/NZ526475A/en unknown
- 2001-12-20 EP EP01991439A patent/EP1345928B1/en not_active Expired - Lifetime
- 2001-12-20 WO PCT/US2001/049585 patent/WO2002050066A2/en not_active Ceased
- 2001-12-20 KR KR10-2003-7008366A patent/KR20030061464A/en not_active Withdrawn
- 2001-12-20 AR ARP010105963A patent/AR040925A1/en active IP Right Grant
- 2001-12-20 CA CA002432872A patent/CA2432872C/en not_active Expired - Fee Related
- 2001-12-21 MY MYPI20015823A patent/MY140377A/en unknown
- 2001-12-25 TW TW095139649A patent/TWI313269B/en not_active IP Right Cessation
- 2001-12-25 TW TW090131846A patent/TWI290551B/en not_active IP Right Cessation
2003
- 2003-06-10 IL IL156369A patent/IL156369A/en not_active IP Right Cessation
- 2003-06-11 IL IL156389A patent/IL156389A/en not_active IP Right Cessation
- 2003-06-12 NO NO20032671A patent/NO20032671L/en not_active Application Discontinuation
- 2003-06-12 NO NO20032670A patent/NO328537B1/en not_active IP Right Cessation
- 2003-06-13 NO NO20032703A patent/NO328501B1/en not_active IP Right Cessation
- 2003-06-13 NO NO20032704A patent/NO330527B1/en not_active IP Right Cessation
- 2003-06-16 NO NO20032736A patent/NO20032736L/en unknown
- 2003-08-01 US US10/632,428 patent/US7531536B2/en not_active Expired - Fee Related
- 2003-11-25 US US10/722,374 patent/US20040157893A1/en not_active Abandoned
- 2003-12-15 US US10/736,426 patent/US7087603B2/en not_active Expired - Fee Related
2004
- 2004-02-10 US US10/775,699 patent/US7427681B2/en not_active Expired - Fee Related
- 2004-12-17 JP JP2004366925A patent/JP2005097322A/en not_active Withdrawn
2006
- 2006-03-21 AU AU2006201267A patent/AU2006201267B2/en not_active Ceased
- 2006-12-20 CY CY20061101823T patent/CY1106297T1/en unknown
2008
- 2008-04-01 JP JP2008095584A patent/JP2008260767A/en not_active Withdrawn
- 2008-04-01 JP JP2008095581A patent/JP2008189682A/en not_active Withdrawn
- 2008-04-03 JP JP2008097620A patent/JP2008222719A/en active Pending
- 2008-04-04 JP JP2008098506A patent/JP2008189687A/en active Pending
- 2008-04-25 US US12/109,598 patent/US8304414B2/en not_active Expired - Fee Related
- 2008-05-07 JP JP2008121727A patent/JP2008247921A/en active Pending
- 2008-05-07 JP JP2008121724A patent/JP2008247920A/en active Pending
- 2008-05-07 JP JP2008121723A patent/JP2008201808A/en active Pending
2009
- 2009-04-17 JP JP2009101481A patent/JP5249842B2/en not_active Expired - Fee Related
- 2009-08-21 US US12/545,347 patent/US7982037B2/en not_active Expired - Fee Related
- 2009-09-14 JP JP2009212566A patent/JP2009286805A/en not_active Withdrawn
2010
- 2010-12-07 IL IL209827A patent/IL209827A0/en unknown
2012
- 2012-09-28 US US13/631,488 patent/US8697698B2/en not_active Expired - Fee Related
2013
- 2013-07-19 JP JP2013150948A patent/JP2013213068A/en active Pending
- 2013-12-24 US US14/139,889 patent/US20140187772A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1060349A1 (en)	2004-08-06
DK1353916T3 (en)	2007-01-29
ES2280313T3 (en)	2007-09-16
IL156407A0 (en)	2004-01-04
WO2002050066A2 (en)	2002-06-27
ES2265450T3 (en)	2007-02-16
AU3116602A (en)	2002-07-01
AU2002246754B2 (en)	2006-06-08
CA2432131A1 (en)	2002-08-01
KR100843114B1 (en)	2008-07-02
NO20032704D0 (en)	2003-06-13
JP2005097322A (en)	2005-04-14
NZ526468A (en)	2004-03-26
MXPA03005612A (en)	2003-10-06
CA2432872A1 (en)	2002-06-27
MXPA03005609A (en)	2003-10-06
JP2008189682A (en)	2008-08-21
IL156389A (en)	2011-01-31
JP4160392B2 (en)	2008-10-01
JP2004517894A (en)	2004-06-17
WO2002059112A3 (en)	2003-02-06
WO2002068415A1 (en)	2002-09-06
DE60126828T2 (en)	2007-11-08
EP1345928A2 (en)	2003-09-24
ATE327989T1 (en)	2006-06-15
IL156368A0 (en)	2004-01-04
NO20032670L (en)	2003-08-15
EP1345925A2 (en)	2003-09-24
AU2002231166B2 (en)	2008-02-21
CN1487933A (en)	2004-04-07
CA2432223A1 (en)	2002-09-06
SI1355905T1 (en)	2007-08-31
ATE528303T1 (en)	2011-10-15
TW200716617A (en)	2007-05-01
EP1355905A1 (en)	2003-10-29
JP2004517927A (en)	2004-06-17
JP2004519479A (en)	2004-07-02
HUP0400908A3 (en)	2010-03-29
EP1345926A2 (en)	2003-09-24
MXPA03005607A (en)	2003-10-06
WO2002066461A1 (en)	2002-08-29
EP1345927A1 (en)	2003-09-24
KR20030061467A (en)	2003-07-18
CA2432132A1 (en)	2002-08-01
JP4160389B2 (en)	2008-10-01
HUP0400842A2 (en)	2004-07-28
ES2265452T3 (en)	2007-02-16
EP1353916A2 (en)	2003-10-22
EP1345922B1 (en)	2006-05-31
WO2002062789A1 (en)	2002-08-15
NO20032736L (en)	2003-08-18
SI1353916T1 (en)	2007-02-28
EP1345925B1 (en)	2006-05-17
ES2272567T3 (en)	2007-05-01
KR20030061858A (en)	2003-07-22
KR20030061468A (en)	2003-07-18
CN100340555C (en)	2007-10-03
KR20030061857A (en)	2003-07-22
ATE326461T1 (en)	2006-06-15
CA2432132C (en)	2008-07-29
JP4234435B2 (en)	2009-03-04
AR042398A1 (en)	2005-06-22
PT1355905E (en)	2007-05-31
DE60126658T2 (en)	2007-11-22
MXPA03005608A (en)	2003-10-06
MXPA03005611A (en)	2003-10-06
CN1486312A (en)	2004-03-31
AP2003002816A0 (en)	2003-06-30
MXPA03005606A (en)	2003-10-06
AR040925A1 (en)	2005-04-27
PL363246A1 (en)	2004-11-15
CA2432129A1 (en)	2002-07-25
CA2432303A1 (en)	2002-08-29
US20090312543A1 (en)	2009-12-17
DE60126658D1 (en)	2007-03-29
NO328537B1 (en)	2010-03-15
EP1345928B1 (en)	2007-02-14
DE60119774D1 (en)	2006-06-22
CA2432222C (en)	2008-07-29
ATE354573T1 (en)	2007-03-15
KR100875091B1 (en)	2008-12-22
CN100406454C (en)	2008-07-30
KR20030061463A (en)	2003-07-18
CY1106297T1 (en)	2011-10-12
CN100436452C (en)	2008-11-26
US6656939B2 (en)	2003-12-02
CN1486310A (en)	2004-03-31
EP1345929A2 (en)	2003-09-24
JP2004518703A (en)	2004-06-24
NO20032671L (en)	2003-08-18
NZ526474A (en)	2005-10-28
NO20032703D0 (en)	2003-06-13
PL363244A1 (en)	2004-11-15
NO328501B1 (en)	2010-03-01
US6653301B2 (en)	2003-11-25
MXPA03005605A (en)	2003-10-06
CA2432129C (en)	2008-08-26
DE60126828D1 (en)	2007-04-05
ATE353890T1 (en)	2007-03-15
EP1353916B1 (en)	2006-09-20
DE60119776T2 (en)	2007-05-16
US8697698B2 (en)	2014-04-15
HK1060347A1 (en)	2004-08-06
CA2432799C (en)	2008-08-19
WO2002050065A2 (en)	2002-06-27
BR0116411A (en)	2003-11-11
NO20032670D0 (en)	2003-06-12
NZ526472A (en)	2004-04-30
KR100909665B1 (en)	2009-07-29
US20130096128A1 (en)	2013-04-18
BR0116493A (en)	2003-09-30
DE60119777D1 (en)	2006-06-22
WO2002050065A3 (en)	2002-10-24
US20040157893A1 (en)	2004-08-12
US6727251B2 (en)	2004-04-27
NO330527B1 (en)	2011-05-09
JP5249842B2 (en)	2013-07-31
US20040132781A1 (en)	2004-07-08
JP2008201808A (en)	2008-09-04
US7087603B2 (en)	2006-08-08
US7982037B2 (en)	2011-07-19
HUP0400639A2 (en)	2004-06-28
EP1345929B1 (en)	2006-05-17
NZ526473A (en)	2005-06-24
IL156408A0 (en)	2004-01-04
HUP0400641A3 (en)	2010-03-29
DK1355905T3 (en)	2007-06-18
CA2432131C (en)	2008-07-08
MXPA03005610A (en)	2003-10-06
US8304414B2 (en)	2012-11-06
JP4210520B2 (en)	2009-01-21
US6989385B2 (en)	2006-01-24
WO2002059112A2 (en)	2002-08-01
IL209827A0 (en)	2011-02-28
JP2008247921A (en)	2008-10-16
US20030105090A1 (en)	2003-06-05
JP2004516291A (en)	2004-06-03
JP4160395B2 (en)	2008-10-01
HK1060557A1 (en)	2004-08-13
NO20032704L (en)	2003-08-21
HUP0400908A2 (en)	2004-07-28
AU2006201267B2 (en)	2010-07-29
US7625913B2 (en)	2009-12-01
US20040167141A1 (en)	2004-08-26
WO2002059111A3 (en)	2003-01-09
CN1486311A (en)	2004-03-31
US20080287444A1 (en)	2008-11-20
WO2002050066A3 (en)	2003-01-23
DE60120219T2 (en)	2007-04-12
US20030004164A1 (en)	2003-01-02
JP2013213068A (en)	2013-10-17
RU2355688C2 (en)	2009-05-20
ATE340172T1 (en)	2006-10-15
JP2004517926A (en)	2004-06-17
ES2266095T3 (en)	2007-03-01
AR042397A1 (en)	2005-06-22
DE60123283D1 (en)	2006-11-02
DE60119776D1 (en)	2006-06-22
NZ526471A (en)	2005-08-26
KR100889246B1 (en)	2009-03-19
NO20032736D0 (en)	2003-06-16
WO2002059111A2 (en)	2002-08-01
US20040214814A1 (en)	2004-10-28
KR100947185B1 (en)	2010-03-15
AP2003002825A0 (en)	2003-09-30
HK1062565A1 (en)	2004-11-12
US20030055068A1 (en)	2003-03-20
HK1060346A1 (en)	2004-08-06
ATE326462T1 (en)	2006-06-15
MY140377A (en)	2009-12-31
TWI313269B (en)	2009-08-11
HUP0400641A2 (en)	2004-06-28
EP1345922A1 (en)	2003-09-24
PL210414B1 (en)	2012-01-31
HK1062433A1 (en)	2004-11-05
DE60119774T2 (en)	2007-05-16
NO20032671D0 (en)	2003-06-12
AU2006201267A1 (en)	2006-04-27
US20050038023A1 (en)	2005-02-17
US20030078275A1 (en)	2003-04-24
ES2265446T3 (en)	2007-02-16
WO2002057259A3 (en)	2003-04-24
PT1345922E (en)	2006-09-29
EP2264028A1 (en)	2010-12-22
IL156369A0 (en)	2004-01-04
CN102250071A (en)	2011-11-23
ATE326463T1 (en)	2006-06-15
JP2004516292A (en)	2004-06-03
DE60119777T2 (en)	2007-05-03
EP1702920A1 (en)	2006-09-20
JP2008247920A (en)	2008-10-16
US6653300B2 (en)	2003-11-25
EP1702920B1 (en)	2011-10-12
JP2008189687A (en)	2008-08-21
JP2008222719A (en)	2008-09-25
ES2375491T3 (en)	2012-03-01
IL156389A0 (en)	2004-01-04
US20140187772A1 (en)	2014-07-03
TWI290551B (en)	2007-12-01
CA2432799A1 (en)	2002-06-27
JP2008260767A (en)	2008-10-30
IL156369A (en)	2011-02-28
AU2002255452B2 (en)	2006-06-08
JP2004518743A (en)	2004-06-24
CN100408573C (en)	2008-08-06
DE60123283T2 (en)	2007-04-12
US20030022885A1 (en)	2003-01-30
HUP0400638A2 (en)	2004-06-28
DE60119775T2 (en)	2007-05-10
US7427681B2 (en)	2008-09-23
NO20032703L (en)	2003-08-19
PT1353916E (en)	2007-01-31
HK1059776A1 (en)	2004-07-16
US20030036543A1 (en)	2003-02-20
PL210066B1 (en)	2011-11-30
HUP0400639A3 (en)	2010-03-29
NZ526470A (en)	2006-03-31
JP2009155352A (en)	2009-07-16
WO2002057259A2 (en)	2002-07-25
KR20030061465A (en)	2003-07-18
CA2432222A1 (en)	2002-08-15
DE60119775D1 (en)	2006-06-22
ATE326460T1 (en)	2006-06-15
DK1345922T3 (en)	2006-09-18
EP1345926B1 (en)	2006-05-17
NZ526475A (en)	2005-06-24
JP2009286805A (en)	2009-12-10
AR042169A1 (en)	2005-06-15
CA2432303C (en)	2010-04-13
EP1355905B1 (en)	2007-02-21
AU2001297619B2 (en)	2006-06-08
CA2432223C (en)	2008-05-20
CA2432872C (en)	2008-09-23
RU2003122209A (en)	2005-02-10
EP1345927B1 (en)	2006-05-17
KR20030061466A (en)	2003-07-18
NZ526469A (en)	2005-10-28
KR20030061464A (en)	2003-07-18
US6664247B2 (en)	2003-12-16
US7531536B2 (en)	2009-05-12
DE60120219D1 (en)	2006-07-06
CN1549812A (en)	2004-11-24
HK1061389A1 (en)	2004-09-17
AP1588A (en)	2006-03-06
US20030004161A1 (en)	2003-01-02

Publication	Publication Date	Title
AU2002231166A1 (en)	2002-09-05	Pyrazole compounds useful as protein kinase inhibitors
AU2002234047A1 (en)	2002-07-01	Pyrazole compounds useful as protein kinase inhibitors
MXPA03002293A (en)	2003-06-06	Pyrazole compounds useful as protein kinase inhibitors
AU2001249865A1 (en)	2001-10-30	Pyrazoles for inhibiting protein kinase
AU2002305260A1 (en)	2002-11-11	Pyrazole derived kinase inhibitors
AU2001237041A1 (en)	2001-11-08	Kinase inhibitors
IL182428A0 (en)	2007-07-24	Indolylmaleimide derivatives as protein kinase c inhibitors
AU2002357193A1 (en)	2003-07-09	Thienopyrimidine compounds as protein tyrosine kinase inhibitors
AU2001247882A1 (en)	2001-10-08	Tricyclic protein kinase inhibitors
AU2576501A (en)	2001-06-18	Protein kinase inhibitors
SI1318997T1 (en)	2006-12-31	Pyrazole compounds useful as protein kinase inhibitors
AU2006201396C1 (en)	2009-02-12	Pyrazole Compounds Useful As Protein Kinase Inhibitors
SI1345922T1 (en)	2006-12-31	Pyrazole compounds useful as protein kinase inhibitors
HK1051540A (en)	2003-08-08	Pyrazoles for inhibiting protein kinases
ZA200301704B (en)	2004-03-01	Triazole compounds useful as protein kinase inhibitors.
HK1057745A (en)	2004-04-16	Imidazole derivatives as raf kinase inhibitors
HK1057039A (en)	2004-03-12	Fused pyrazole derivatives being protein kinase inhibitors
AU2002246255A1 (en)	2002-10-21	Jun kinase inhibitors
DK1317448T4 (en)	2011-05-30	Pyrazole compounds useful as protein kinase inhibitors